Journals / Turkish Journal of Hematology / 2013 / Cilt: 30 - Sayı: 2

Kanama durdurucu ajanın (Ankaferd Blood Stopper) kemik yüzeylerine etkisinin deneysel olarak incelenmesi

Experimental investigation of the effects of a blood stopper agent (Ankaferd Blood Stopper) on bone surfaces

Pages
177–183
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also new bone formation was scored according to the histologic evaluation Results: The results showed that while new the to day 7 experimental group showed much more bone formation than the to day 7 control group, there was no significant difference between the to day 28 and day 42 experimental groups and to day 28 and day 42 control groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aims to experimentally investigate the efficiency of Ankaferd Blood Stopper (ABS) on early and long- term bone healing and its effects on bone surfaces.
📊
Key Findings & Data:A 3.0-mm-deep monocortical circular defect was created with a 3.0 mm diameter trephine drill on the proximal part of the femur, and 0.05 mL ABS was applied to the experimental group while the control group was left untreated.
💡
Conclusion & Impact:Also new bone formation was scored according to the histologic evaluation Results: The results showed that while new the to day 7 experimental group showed much more bone formation than the to day 7 control group, there was no significant difference between the to day 28 and day 42 experimental groups and to day 28 and day 42 control groups.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: This study aims to experimentally investigate the efficiency of Ankaferd Blood Stopper (ABS) on early and long- term bone healing and its effects on bone surfaces. Materials and Methods: Thirty adult male Wistar albino rats were used in the study. These rats were randomly divided into three groups, and bilaterally bone defects were created in the femur of each rat. A 3.0-mm-deep monocortical circular defect was created with a 3.0 mm diameter trephine drill on the proximal part of the femur, and 0.05 mL ABS was applied to the experimental group while the control group was left untreated. Group 1, group 2, and group 3 rats were sacrificed on days 7, 28, and 42, respectively. Trabecular bone area (Tb.Ar), medullary bone diameter (Me.Dm), osteoblast area (Ob.Ar), osteoid area (O.Ar) and mineralized bone area (Md.Ar) were examined in the histomorphometric analysis. Also new bone formation was scored according to the histologic evaluation Results: The results showed that while new the to day 7 experimental group showed much more bone formation than the to day 7 control group, there was no significant difference between the to day 28 and day 42 experimental groups and to day 28 and day 42 control groups. Accordingly, ABS applied in bone cavities only had a larger accelerator effect on bone healing for the seventh-day to day 7 experimental group. In clinical observations, no allergic or inflammatory reactions were observed on the skin and other preoperative and postoperative periods. Moreover in, the histomorphometric study, necrotic areas and infection areas were not observed. Conclusion: ABS has an acceleratory effect on the short-term bone healing process and is a reliable agent for routine use. However, its effects on the long-term bone healing process are insignificant. We think that a wide series of research projects are required to confirm the effects of ABS speeding up the healing process in addition to its characteristic as a blood stopping agent.

Özet

Amaç: Çalışmamızda deneysel olarak Ankaferd Blood Stopper (ABS)’ın erken ve geç dönem kemik iyileşmesi ve kemik yüzeylere etkisinin incelenmesi amaçlanmıştır. Gereç ve Yöntemler: Çalışmaya 30 yetişkin erkek Wistar albino rat dahil edilmiştir. Denekler rastgele üç grubu ayrılmış ve kemik defektleri her bir femura uygulanmıştır. Kemik defektleri femurun proksimal kısmında 3,0 mm çapında trefin frez yardımıyla 3,0 mm derinliğinde, monokortikal ve dairesel olarak hazırlanmıştır. Deney grubuna 0,5 mL ABS uygulanırken kontrol grubuna herhangi bir madde uygulanmamıştır. Denekler 3 gruba ayrılarak sırasıyla yedinci, yirmi sekizinci ve kırk ikinci günlerde sakrifiye edilmiştir. Örneklerin histomorfometrik analizlerinde trabeküler kemik yüzey alanı, medullar kemik çapı, osteoblast yüzey alanı, osteoid kemik yüzey alanı ve mineralize kemik yüzey alanları incelenmiştir. Yeni kemik oluşumunun histolojik değerlendirmesi yapılarak, yeni kemik oluşum skorlaması yapılmıştır. Bulgular: Çalışmamız sonucunda ABS kemik kavitelerinde uygulanmasının 7. gün deney grubunda kemik iyileşmesini hızlandırıcı etkileri üzerine daha net bulgulara ulaşılmış ve 7. gün sonuçlarına göre yeni kemik yapımını deney grubunda fazla olarak bulunmuştur. Ankaferd Blood Stopper kemik kavitelerinde uygulanmasının 28. ve 42. gün deney ve kontrol gruplarında benzer sonuçlara ulaşılmıştır. Klinik gözlemlerde intraoperatif ve postoperatif dönemde cilt ve diğer dokularda alerjik ve iltihabi reaksiyonlar gözlenmemiştir. Ayrıca histomorfometrik çalışmalarda nekrotik alanlara ve enfeksiyoz reaksiyonlara rastlanmamıştır. Sonuç: Sonuç olarak, ABS kısa dönem kemik iyileşmesinde olumlu etkileri olabileceği gösterilirken, uzun dönem de kemik yapımını artırıcı etkileri olduğu gösterilmemiştir. Bununla birlikte ameliyat öncesi ve sonrasında herhangi bir yabancı cisim reaksiyonu veya nekrotik alanlara rastlanılmaması ve komplikasyon oluşturmaması pozitif etkileri olarak değerlendirilebilir. Ankaferd Blood Stopper’in kanama durdurucu ajan olmasının yanında kemik iyileşmesini hızlandırıcı etkileri, geniş serili araştırmalarla desteklenmesi gerektiğini düşünmekteyiz.

🔖

Cite This Article

ŞİMŞEK, H. O., TÜZÜM, M. Ş., baykul, T., GÜRER, İ. E., BAŞSORGUN, C. İ. (2013). Kanama durdurucu ajanın (Ankaferd Blood Stopper) kemik yüzeylerine etkisinin deneysel olarak incelenmesi. Turkish Journal of Hematology, Cilt: 30 - Sayı: 2, 177–183. https://ajindex.com/articles/412598

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Israels S, Schwetz N, Boyar R, McNicol A. Bleeding disorders: characterization, dental considerations and management. J Can Dent Assoc 2006;72:827
  2. Peterson LJ, Ellis E, Hupp JR, Tucker MR. Contemporary Oral and Maxillofacial Surgery. 3rd ed. St. Louis: Mosby, 1998
  3. Oz MC, Rondinone JF, Shargill NS. Floseal matrix: new generation topical hemostatic sealant. J Card Surg 2003;18:486-493
  4. Sabel M, Stummer W. The use of local agents: Surgicel and surgifoam. Eur Spine J 2004;13:97-101
  5. Seyednejad H, Imami M, Jameieson T, Seifalian AM. Topical haemostatic agents. Brit J Surg 2008;95:1197- 1225
  6. Schonauer C, Tessitore E, Barbagallo G, Albanese V, Moraci A. The use of local agents: bone wax, collagen, oxidized cellulose. Eur Spine J 2004;13:89-96
  7. Goker H, Haznedaroglu IC, Ercetin S, Kirazli S, Akman U, Ozturk Y, Firat HC. Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper. J Int Med Res 2008;36:163-170
  8. Haznedaroglu BZ, Beyazit Y, Walker SL, Haznedaroglu IC. Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat. Crit Rev Oncol Hematol 2012;83:21-34
  9. Huri E, Akgül T, Yücel MÖ, Astarçı HM, Üstün H, Germiyanoğlu RC. The second step in vitro trial of Ankaferd Bloodstopper: comparison with the other hemostatic agents. Turk J Med Sci 2011;41:7-15
  10. Kurt M, Akdoğan M, Onal IK, Kekilli M, Arhan M, Shorbagi A, Aksu S, Kurt OK, Haznedaroglu IC. Endoscopic topical application of Ankaferd Blood Stopper for neoplastic gastrointestinal bleeding: a retrospective analysis. Dig Liver Dis 2010;42:196-199
  11. Ulus TA, Turan NN, Ozyalcin S, Aydog G, Ulus F, Göker H, Haznedaroğlu IC. Surgical and histopathological effects of topical Ankaferd hemostat on major arterial vessel injury in relation to the enhanced intra-arterial blood pressure. Turk J Hematol 2011;28:206-212
  12. Teker AM, Korkut AY, Gedikli O, Kahya V. Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis. Eur Arch Otorhinolaryngol 2010;267:1377-1381
  13. Karakaya K, Ucan HB, Tascılar O, Emre AU, Cakmak GK, Irkorucu O, Ankarali H, Comert M. Evaluation of a new hemostatic agent Ankaferd Blood Stopper in experimental liver laceration. J Invest Surg 2009;22:201-206
  14. Koşar A, Cipil HS, Kaya A, Uz B, Haznedaroğlu IC, Goker H, Ozdemir O, Erçetin S, Kirazli S, Firat HC. The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic ab